Rick Heida received his Master’s degree in Biomedical Sciences from the University of Groningen in 2017, specializing in immunology and microbiology. Currently, he is pursuing a PhD degree at the Department of Pharmaceutical Technology and Biopharmacy at the University of Groningen under the supervision of Dr. Erik Frijlink, Dr. Anke Huckriede and Dr. Wouter Hinrichs. His research focuses mainly on the evaluation of antiviral entry inhibitors with broad-spectrum potential and their suitability to be formulated as stable dry-powder formulations for inhalation. In line with this, he is working on optimizing methods for the pulmonary administration of dry-powder formulations to small laboratory animals. Main research interests: immunology of infectious diseases (primarily viruses); drug formulation sciences; novel vaccine (delivery) strategies; development of antiviral drugs; pulmonary administration of drugs and vaccines; and mucosal immunity.